¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reverse passive hemagglutination"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reverse transcription
    ¿ªÀü»ç
  • reverse Waters position
    ¿ª¿öÅͽºÀÚ¼¼
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • passive
    ¼öµ¿-, Çǵ¿-
  • passive aggressive personality
    ¼öµ¿°ø°ÝÀΰÝ
  • passive congestion
    ¼öµ¿¿ïÇ÷
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • passive diffusion
    ¼öµ¿È®»ê
  • passive edema
    ¼öµ¿ºÎÁ¾
  • passive euthanasia
    ¼Ò±ØÀû¾È¶ô»ç
  • passive exercise
    Çǵ¿¿îµ¿
  • passive hyperemia
    ¼öµ¿ÃæÇ÷
  • passive immunity
    ¼öµ¿¸é¿ª
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • passive movement
    ¼öµ¿¿îµ¿, Çǵ¿¿îµ¿
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • immune adherence hemagglutination
    ¸é¿ªºÎÂøÀûÇ÷±¸ÀÀÁý
  • indirect hemagglutination
    °£Á¢ÀûÇ÷±¸ÀÀÁý¹ý
  • sensitized hemagglutination
    ¹Î°¨ÀûÇ÷±¸ÀÀÁý
  • spike hemagglutination
    ÀûÇ÷±¸ÀÀÁýµ¹±â
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • passive congestion
    ¼öµ¿¿ïÇ÷
  • passive diffusion
    ¼öµ¿È®»ê
  • passive edema
    ¼öµ¿ºÎÁ¾
  • passive euthanasia
    ¼öµ¿¾È¶ô»ç
  • passive exercise
    Çǵ¿¿îµ¿
  • passive hyperemia
    ¼öµ¿ÃæÇ÷
  • passive immunity
    ¼öµ¿¸é¿ª
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination =HA
    ÀûÇ÷±¸ÀÀÁý(¹ÝÀÀ)(îåúìϹëêó¢Úãëë).
  • hemagglutination =HA
    (Àû)Ç÷±¸ÀÀÁý(¹ÝÀÀ)(ËøÌ´Ë´Ëô̤ËÑËô).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination test
    (Àû)Ç÷±¸ÀÀÁý½ÃÇè
  • hemagglutination test
    Ç÷±¸ÀÀÁý¹ý
  • hemagglutination test
    Ç÷±¸ÀÀÁý °Ë»ç
  • hemagglutination test
    (Àû)Ç÷±¸ÀÀÁý½ÃÇè.
  • hemagglutination, immune adherence
    ¸é¿ªºÎÂø Ç÷±¸ÀÀÁý
  • hemagglutination, indirect
    °£Á¢Ç÷±¸ÀÀÁý¹ý
  • hemagglutination, spike
    Ç÷±¸ÀÀÁýµ¹±â
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reverse mutation =back m.
    º¹±Í(µ¹¿¬)º¯ÀÌ(ÜÖÏýÔÍæÔܨì¶).
  • reverse mutation =back m.
    º¹±Í(µ¹¿¬)º¯ÀÌ(ÜÖÏýÔÍæÔܨì¶).
  • reverse osmosis
    ¿ª»ïÅõ(æ½ß¶÷â).
  • reverse phase liquid chromatography
    ¿ª»ó¾×üũ·Î¸¶Åä±×·¡ÇÇ
  • reverse piezoelectric effect
    ¿ª ¾ÐÀüÈ¿°ú
  • reverse transcriptase
    ¿ªÀü»ç È¿¼Ò
  • reverse transcriptase
    ¿ªÀüÆ®·£½ºÅ©¸³Å×ÀÌÁî
  • reverse transcriptase
    ¿ªÀü»çÈ¿¼Ò
  • reverse transcription
    ¿ªÀü»ç
  • reverse transcription
    ¿ªÀü»ç(æ½ï®ÞÐ).
  • spiral reverse bandage
    ³ª¼±¿ªÇàºØ´ë(¡­¿ªÇàºØ´ë).
  • transcriptase, reverse
    ¿ªÀü»çÈ¿¼Ò
  • hemagglutination
    Ç÷±¸ÀÀÁý
  • hemagglutination
    (Àû)Ç÷±¸ÀÀÁý(¹ÝÀÀ)
  • hemagglutination =HA
    (Àû)Ç÷±¸ÀÀÁý(¹ÝÀÀ)(ËøÌ´Ë´Ëô̤ËÑËô).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive spread
    ¼öµ¿ ÀüÆÄ(áôÔÑîî÷ë)
  • passive transfer
    ¼öµ¿ À̵¿(áôÔÑì¹ÔÑ)
  • passive transport
    ¼öµ¿ ¼ö¼Û(áôÔÑâÃáê)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PHI passive hemagglutination inhibition; past history of illness; phosphohexose isomerase; physiological...
RPHA reversed passive hemagglutination
RPHAMFCA reversed passive hemagglutination by miniature centrifugal fast analysis
IHA idiopathic hyperaldosteronism; indirect hemagglutination; indirect hemagglutination antibody
rT3 reverse T3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IHA Indirect Hemagglutination assay
CPM Continuous passive motion
FPT Failure of passive transfer
PAR Passive Anterior Rhinomanometry
PAR Passive Avoidance Response
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • continuous passive motion
    Áö¼ÓÀûÀÎ ¼öµ¿ ¿îµ¿, °è¼ÓÀûÀÎ ¼öµ¿ ¿îµ¿, Áö¼ÓÀûÀÎ ¼öµ¿Àû ¿îµ¿
    Á¤ÇØÁø ¿îµ¿ ¹üÀ§³»·Î °üÀýÀ» ¿òÁ÷ÀÌ´Â ±â°è³ª ´Ù¸¥ »ç¶÷¿¡ ÀÇÇØ ÀÌ·ç¾îÁö´Â ½ÅüÀÇ ÁÖ±âÀûÀÎ ¿îµ¿.
  • passive agglutination
    ¼öµ¿ ÀÀÁý
  • passive dependent
    Çǵ¿ ÀÇÁ¸¼º. ¼öµ¿ ÀÇÁ¸¼ºÀÇ
  • passive edema
    ¼öµ¿ ºÎÁ¾
  • passive exercise
    ¼öµ¿Àû ¿îµ¿
  • passive hyperemia
    ¼öµ¿¼º ÃæÇ÷
  • passive movement
    ¼öµ¿ ¿îµ¿, Çǵ¿ ¿îµ¿
  • passive muscle stretching
    ¼öµ¿Àû ±Ù ½ÅÀå
  • passive range of motion
    ¼öµ¿Àû ¿îµ¿ ¹üÀ§
    ´Ù¸¥ »ç¶÷À̳ª ±â°è ¶Ç´Â ¿ÜºÎÀÇ Èû¿¡ ÀÇÇÏ¿© ±³ÇÕ, °ü·Ã °üÀý³¶, Àδë, ±ÙÀ°À¸·Î Àü´ÞµÈ ¿îµ¿.
  • passive resistive stretch
    ¼öµ¿Àû ÀúÇ× ½ÅÀü
    ¹Ý´ëµÇ´Â Èû¿¡ ´ëÇÏ¿© ±ÙÀ°À» Ȱ¼ºÈ­½ÃŲ ´ÙÀ½ ½ÅÀü½ÃÅ´À¸·Î¼­ ±ÙÀ°ÀÇ ±æÀ̸¦ Áõ°¡Çϵµ·Ï °í¾ÈµÈ ¿îµ¿.
  • passive stretch
    ¼öµ¿Àû ½ÅÀå, ¼öµ¿Àû ½ÅÀü
  • passive stretching
    ¼öµ¿Àû ½ÅÀå
  • passive transport
    Çǵ¿Àû ¿î¹Ý, Çǵ¿Àû À̵¿, ¼öµ¿Àû À̵¿
  • passive-aggressive personality
    ¼öµ¿Àû °ø°Ý¼º ÀΰÝ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
reverse transcriptase PCR A technique used to amplify RNA targets. The specimen containing the target RNA (e.g., HIV-1 RNA, Hepatitis C Virus RNA) is subjected to reverse transcription to make complementary DNA (cDNA), which is then, in turn, amplified by PCR.
Acronym: RT-PCR
(05 Mar 2000)
reverse transcription <molecular biology> The process of copying information found in RNA into DNA.
(09 Oct 1997)
reverse transcriptons An enzyme that converts RNA to DNA. Some viruses have only RNA as their primary genetic material. By converting their RNA genes to DNA with this enzyme, the host cell is 'tricked' into creating new copies of the virus. Useful in genetic engineering to make DNA from mRNA.
(14 Nov 1997)
reverse Trendelenburg position Supine position without flexing or extending, in which the head is higher than the feet.
(05 Mar 2000)
HIV-1 reverse transcriptase <enzyme> HIV-1 enzyme responsible for the synthesis of DNA from genomic RNA of the virus. It is encoded by the pol gene of HIV-1.
Registry number: EC 2.7.7.-
(12 Dec 1998)
HIV-2 reverse transcriptase <enzyme> Responsible for synthesis of double-stranded DNA from the genomic RNA of the virus; has rnase h and DNA-dependent DNA polymerase activities; was indexed as reverse transcriptase (87-91)
Registry number: EC 2.7.7.-
(26 Jun 1999)
DNA reverse gyrase <enzyme> A topoisomerase II subclass which introduces positive superhelical turns into DNA
Registry number: EC 3.1.-
Synonym: reverse gyrase
(26 Jun 1999)
triiodothyronine, reverse <chemical> 0-(4-hydroxy-3,5-diiodophenyl)-3-iodo-l-tyrosine. A metabolite of thyroxine formed by the peripheral degradation of thyroxine as a result of the tyrosyl or inner ring 5-deiodination. In systemic disease states or in neonates, levels of triiodothyronine are low and those of reverse triiodothyronine are elevated. Reverse t3 is therefore useful as a diagnostic aid and in the treatment of foetal and infantile hypothyroidism.
Chemical name: L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo-
(12 Dec 1998)
artificial passive immunity See: acquired immunity.
(05 Mar 2000)
passive Neither spontaneous nor active, not produced by active efforts.
Origin: L. Passivus
(18 Nov 1997)
passive agglutination Agglutination of particles that have been coated with soluble antigen, by antiserum specific for the adsorbed antigen.
Synonym: indirect agglutination.
(05 Mar 2000)
passive-aggressive behaviour Apparently compliant behaviour, with intrinsic obstructive or stubborn qualities, to cover deeply felt aggressive feelings that cannot be more directly expressed.
(05 Mar 2000)
passive-aggressive personality A personality disorder in which aggressive feelings are manifested in passive ways, especially through mild obstructionism and stubbornness.
(05 Mar 2000)
passive-aggressive personality disorder A personality disorder characterised by an indirect resistance to demands for adequate social and occupational performance; anger and opposition to authority and the expectations of others that is expressed covertly by obstructionism, procrastination, stubbornness, dawdling, forgetfulness, and intentional inefficiency.
(12 Dec 1998)
passive anaphylaxis A reaction resulting from inoculation of antigen in an animal previously inoculated intravenously with specific antiserum from another animal, a latent period being required between the two inoculations.
Synonym: antiserum anaphylaxis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reverse
    ¿ª;¹Ý´ë;µÚ;¹è¸é;¹èÈÄ;(ÁÖÈ­.¸Þ´ÞµîÀÇ)µÞ¸é;(ÆîÄ£ Ã¥ÀÇ)¿ÞÂÊÆäÀÌÁö;Àüµµ;(ÀÚµ¿Â÷ÀÇ)ÈÄÁø;ÈÄÁø±â¾î;¿ªÀü(¿ªÁø)ÀåÄ¡;¿ªÀü;¿ª(ÁÂ)ȸÀü;°³¸Ó¸®ÆÇ;µÚ³¡(â.ÃѵîÀÇ);ºÒ¿î;½ÇÆÐ;ÆÐ¹è;°Å²Ù·ÎÀÇ;»ó¹ÝµÇ´Â;µÚ(À̸é)ÀÇ;¹èÈÄÀÇ;µÚ·Î ÇâÇÑ;¿ªÀüÇÏ´Â;ÈÄÅð¿ëÀÇ;(À§Ä¡.¹æÇâ.¼ø¼­µîÀ»)°Å²Ù·Î
  • reverse advertising
    ¿ª±¤°í(¼ÒºñÀÚ°¡ ±×ÀÇ ¿ä±¸¸¦ µ¥ÀÌÅͺ£À̽º¿¡ ÀÔ·ÂÇÏ¸é °ø±ÞÀÚ°¡ ±×°ÍÀ» º¸°í °í°´À» ã¾Æ³»´Â ¹æ¹ý)
  • reverse angle
    ¿ª°¢µµ(Ä«¸Þ¶ó À§Ä¡¸¦ ¹Ù²Ù¾î ÁÖ¿ä ÇÇ»çüÀÇ µÚ·Î µ¹¾Æ ´ë¸éÇϰí ÀÖ´Â ¸®Æ÷Å͸¦ ºñÄ¡´Â ¹æ¹ý)
  • reverse commuting
    ¿ª¹æÇâ Åë±Ù(µµ½Ã¿¡¼­ ±³¿Ü·Î)
  • reverse culture shock
    ¿ª¹®È­ ¼îÅ©(¿Ü±¹¿¡¼­ ¿À·§µ¿¾È »ýȰÇÑ »ç¶÷ÀÌ °í±¹À¸·Î µ¹¾Æ¿ÔÀ» ¶§ ´À³¢´Â ¼Ò¿Ü°¨)
  • reverse discrimination
    ¿ªÂ÷º°(ÇÇÂ÷º°ÀÚ ¿ì´ë·Î »ý±â´Â ±×¹ÛÀÇ »ç¶÷ÀÇ ºÒ¸®)
  • reverse engineering
    ºÐÇØ °øÇÐ;¿ª¼³°è(½ÅÁ¦Ç°À» ¼³°èÇÏ¿© ±¸Á¶¸¦ Á¤¹ÐÇÏ°Ô ºÐ¼®.±× ¼³°è¸¦ ¿ªÀ¸·Î ŽÁöÇÏ´Â ±â¼ú)
  • reverse gear
    (ÀÚµ¿Â÷ÀÇ)ÈÄÁø ±â¾î
  • reverse racism
    ¿ªÀÎÁ¾ Â÷º°(ÈæÀÎ.¼Ò¼ö ¹ÎÁ·ÀÇ Â÷º°ÆóÁö ¶§¹®¿¡ ¹éÀÎÀÌ ÀÔÇÐ.Ãë¾÷¿¡¼­ ¿ÀÈ÷·Á ºÒ¸®ÇØ Áö´Â »óÅÂ)
  • reverse transcriptase
    ¿ªÀü»çÈ¿¼Ò(RNA¿¡ ÀÇÁ¸ÇÏ¿© DNA¸¦ ÇÕ¼º½ÃŰ´Â È¿¼Ò)
  • reverse-charge
    (ÅëÈ­¿ä±ÝÀÌ)¼ö½ÅÀÎ ÁöºÒÀÇ
  • reverse-engineered
    ºÐÇØÇÏ¿© ¸ð¹æÇÑ(¹ÝµµÃ¼¿¡ ´ëÇÏ¿© ÈçÈ÷ ¾¸)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á